相关实验视频
Updated: May 15, 2025

05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.0K
甲基受体1及其对手T0080在动脉样硬化中的作用
Yu-Jing Li1,2, Xue Zhao1, Siting Wu1
1Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Cell death and differentiation
|April 9, 2025
概括
甲基受体1 (FPR1),在动脉样硬化患者中升高,通过激活巨细胞来驱动动动脉损伤. 用T0080抑制FPR1减少了小鼠的斑块形成和炎症,这表明了动脉样硬化的新治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
背景情况:
- 动脉样硬化包括巨细胞驱动的炎症和动脉损伤.
- 调节这些致病过程的机制尚未完全理解.
研究的目的:
- 研究甲基受体1 (FPR1) 在动脉样硬化中的作用.
- 评估FPR1抑制的治疗潜力.
主要方法:
- 在动脉样硬化患者中测量FPR1激动剂水平.
- 在动脉样硬化病变中检查FPR1的表达.
- 在阿波利波蛋白E缺陷 (ApoE-/-) 的小鼠中使用了巨细胞特异性Fpr1淘汰.
- 向ApoE-/-小鼠使用FPR1抗剂T0080.
主要成果:
- 患者的FPR1激动剂水平与大脑动脉狭窄相关.
- 大细胞FPR1的删除减少了动脉样硬化斑块和炎症.
- FPR1的激活促进了巨细胞的ROS,TNF-α和IL-1β的产生,诱导了内皮细胞和光滑肌肉细胞的亡.
- 在小鼠中,T0080治疗减轻了动脉样硬化进展.
结论:
- 在巨细胞介导动脉样硬化中,FPR1起着至关重要的作用.
- 抑制FPR1是一种有前途的动脉样硬化治疗策略.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Inflammation
51.8K
Overview
51.8K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
120
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
120

